SUMMIT THERAPEUTICS ($SMMT) posted quarterly earnings results on Monday, October 20th. The company reported earnings of -$0.31 per share, missing estimates of -$0.13 by $0.18. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $SMMT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SUMMIT THERAPEUTICS Insider Trading Activity
SUMMIT THERAPEUTICS insiders have traded $SMMT stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SMMT stock by insiders over the last 6 months:
- ROBERT W DUGGAN (Co-Chief Executive Officer) has made 2 purchases buying 338,394 shares for an estimated $5,984,755 and 0 sales.
- MAHKAM ZANGANEH (Co-Chief Executive Officer) has made 2 purchases buying 338,394 shares for an estimated $5,984,755 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SUMMIT THERAPEUTICS Hedge Fund Activity
We have seen 139 institutional investors add shares of SUMMIT THERAPEUTICS stock to their portfolio, and 115 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BAKER BROS. ADVISORS LP added 9,298,109 shares (+38.1%) to their portfolio in Q2 2025, for an estimated $197,863,759
- VANGUARD GROUP INC removed 2,966,835 shares (-25.5%) from their portfolio in Q2 2025, for an estimated $63,134,248
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,652,656 shares (-40.5%) from their portfolio in Q2 2025, for an estimated $56,448,519
- BALYASNY ASSET MANAGEMENT L.P. removed 1,703,180 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $36,243,670
- BLACKROCK, INC. removed 1,550,889 shares (-18.5%) from their portfolio in Q2 2025, for an estimated $33,002,917
- NORGES BANK added 1,289,862 shares (+1289.9%) to their portfolio in Q2 2025, for an estimated $27,448,263
- APEIRON CAPITAL LTD added 1,200,941 shares (+inf%) to their portfolio in Q2 2025, for an estimated $25,556,024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SUMMIT THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $SMMT in the last several months. We have seen 7 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 09/08/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/08/2025
- JMP Securities issued a "Market Outperform" rating on 08/19/2025
- Evercore ISI Group issued a "Outperform" rating on 08/12/2025
- UBS issued a "Buy" rating on 07/01/2025
- Leerink Partners issued a "Underperform" rating on 06/11/2025
- Goldman Sachs issued a "Buy" rating on 05/02/2025
To track analyst ratings and price targets for SUMMIT THERAPEUTICS, check out Quiver Quantitative's $SMMT forecast page.
SUMMIT THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $SMMT recently. We have seen 12 analysts offer price targets for $SMMT in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Etzer Darout from Barclays set a target price of $13.0 on 09/17/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $50.0 on 09/16/2025
- Brad Canino from Guggenheim set a target price of $40.0 on 09/04/2025
- Reni J. Benjamin from JMP Securities set a target price of $40.0 on 09/03/2025
- Kelsey Goodwin from Piper Sandler set a target price of $21.0 on 08/19/2025
- Cory Kasimov from Evercore ISI Group set a target price of $34.0 on 08/12/2025
- David Dai from UBS set a target price of $30.0 on 07/01/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
